Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.175, up 2.08% on the day, but remains in a pronounced bearish technical trend with all moving averages signaling sell. The ETF is designed to deliver twice the daily return of Coinbase stock (COIN), which has experienced significant volatility. Recent news highlights substantial losses, with CONL down 67% year-to-date as of June 2026, illustrating the high-risk nature of leveraged products.

The outlook is highly speculative and carries extreme risk due to the ETF's daily reset leverage, which can lead to rapid value erosion during volatile periods. Investment opportunity is limited to aggressive, short-term traders who can manage the volatility tax. The primary risk is the structural decay associated with daily rebalancing in a choppy market for the underlying asset.

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.